TMCNET eNEWSLETTER SIGNUP

Allergan Comments on Pershing Square's Definitive Proxy Solicitation

Allergan, Inc. (NYSE: AGN (News - Alert)) ("Allergan" or the "Company") today provided
the following comment in response to the definitive proxy solicitation
filed by Pershing Square Capital Management, L.P. ("Pershing Square") in
connection with Pershing Square's request to call a Special Meeting of
Stockholders (the "Special Meeting"). At the Special Meeting, if called,
Allergan stockholders would be asked to remove a majority of the
Company's existing directors in connection with Valeant Pharmaceuticals
International, Inc.'s ("Valeant") unsolicited exchange offer to acquire
all outstanding common shares of Allergan for 0.83 shares of Valeant
common stock and $72.00 in cash, or subject to proration, an amount of
cash or a number of Valeant common shares with the implied value set
forth in the exchange offer (the "Exchange Offer").

Under the current Board's leadership, which includes individuals with
significantly more industry experience than Pershing Square's
recommended nominees, Allergan continues to execute on its plan to drive
near- and long-term organic growth, enhance its growth prospects and
continue generating significant value for all of Allergan's
stockholders. We believe Pershing Square's attempt to replace a majority
of the Allergan Board is a further effort to support Valeant in its bid
to acquire Allergan at a grossly inadequate price that substantially
undervalues the Company and creates significant risks and uncertainties
for Allergan stockholders. Valeant has repeatedly failed to address the
serious concerns raised by Allergan and important members of the
investment community about Valeant's anemic organic growth driven by
unsustainable price increases, among other fundamental business model
issues.

Allergan has a track record of consistently acting in the best interests
of its stockholders and the Board remains confident in the Company's
ability to create significantly more value than Valeant's proposal.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial
advisors to the Company and Latham & Watkins, Richards, Layton & Finger,
P.A. and Wachtell, Lipton, Rosen & Katz are serving as legal counsel to
the Company.

About Allergan

Allergan is a multi-specialty health care company established more than
60 years ago with a commitment to uncover the best of science and
develop and deliver innovative and meaningful treatments to help people
reach their life's potential. Today, we have approximately 11,600 highly
dedicated and talented employees, global marketing and sales
capabilities with a presence in more than 100 countries, a rich and
ever-evolving portfolio of pharmaceuticals, biologics, medical devices
andover-the-counter consumer products, and state-of-the-art resources
in R&D, manufacturing and safety surveillance that help millions of
patients see more clearly, move more freely and express themselves more
fully. From our beginnings as an eye care company to our focus today on
several medical specialties, including eye care, neurosciences, medical
aesthetics, medical dermatology, breast aesthetics, and urologics,
Allergan is proud to celebrate more than 60 years of medical advances
and proud to support the patients and customers who rely on our products
and the employees and communities in which we live and work. For more
information regarding Allergan, go to: www.allergan.com

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including but not limited to statements
regarding a proposed offer or proposal by Valeant and/or Pershing
Square. These forward-looking statements are made as of the date they
were first issued and are based on current expectations as well as the
beliefs and assumptions of management. Forward-looking statements are
subject to a number of risks and uncertainties, many of which involve
factors or circumstances that are beyond Allergan's control. Allergan
expressly disclaims any intent or obligation to update these
forward-looking statements except as required by law. Additional
information concerning these and other risks can be found in press
releases issued by Allergan, as well as Allergan's public filings with
the U.S. Securities and Exchange Commission (the "SEC (News - Alert)"), including the
discussion under the heading "Risk Factors" in Allergan's most recent
Annual Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q. Copies of Allergan's press releases and additional information
about Allergan are available at www.allergan.com
or you can contact Allergan's information agent, Innisfree M&A
Incorporated, at 877-800-5187.

Important Additional Information

This communication does not constitute an offer to buy or solicitation
of an offer to sell any securities. The Company has filed a
solicitation/recommendation statement on Schedule 14D-9 with the SEC
that has been mailed to stockholders of the Company. In addition, the
Company has filed a preliminary solicitation statement with the SEC on
June 16, 2014 and intends to file a definitive solicitation statement.
Any definitive solicitation statement will be mailed to stockholders of
the Company. INVESTORS AND STOCKHOLDERS OF ALLERGAN ARE ENCOURAGED TO
READ THESE AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY MAY FILE
WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION. Investors and stockholders will be able to obtain
free copies of these documents as they become available and any other
documents filed with the SEC by the Company at the SEC's website at www.sec.gov.
In addition, copies will also be available at no charge at the Investors
section of the Company's website at www.allergan.com.
Copies of these materials may also be requested from Allergan's
information agent, Innisfree M&A Incorporated, toll-free at 877-800-5187.

The Company, its directors and certain of its officers and employees are
participants in solicitations of Company stockholders. Information
regarding the names of the Company's directors and executive officers
and their respective interests in the Company by security holdings or
otherwise is set forth in the Company's proxy statement for its 2014
annual meeting of stockholders, filed with the SEC on March 26, 2014, as
supplemented by the proxy information filed with the SEC on April 22,
2014. Additional information can be found in the Company's Annual Report
on Form 10-K for the year ended December 31, 2013, filed with the SEC on
February 25, 2014 and its Quarterly Report on Form 10-Q for the quarter
ended March 31, 2014, filed with the SEC on May 7, 2014. To the extent
holdings of the Company's securities have changed since the amounts
printed in the proxy statement for the 2014 annual meeting of
stockholders, such changes have been reflected on Initial Statements of
Beneficial Ownership on Form 3 or Statements of Change in Ownership on
Form 4 filed with the SEC.